Inclusion Criteria:

• Must have received platinum and/or taxane chemotherapy for adjuvant treatment of a solid tumor.
• Screens positive for moderate to severe CIPN with a 4+ on a 0-10 scale, with 0 being no numbness/tingling or pain in hands or feet and 10 being most severe imaginable.
• Last chemo dose must be 6+ months in the past (as noted in A.1, symptoms persist in 30% of recipients > 6 months, this assures those with established chronicity are included, reducing likelihood of spontaneous improvement). Also, no new chemotherapy should be anticipated during the study course.
• Must have internet access.

Exclusion Criteria:  

• Other potential cause of neuropathy (e.g., diabetes).
• Ongoing treatment with a neuropathy-causing medication,.
• History of oncology massage therapy for neuropathy in the last 3 months,
• Unstable lymphedema—if the patient is considered at risk of lymphedema, they can participate because level 2 pressure is deemed safe; however, if patient has had lymphedema, their condition must be declared stable by a certified lymphedema therapist (if stable, level 2 pressure is safe for this study’s interventions).
• Stage IV patients are excluded because many are on active medications that continue to cause or exacerbate neuropathy, and would confound results; active metastases introduce increased risks with massage; and general comfort massage for supportive care would be more indicated than targeting CIPN.,

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/11/23. Questions regarding updates should be directed to the study team contact.